Remember me
2. Toni KC, Thomas P, Mauricio B, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 2021 Mar 4;384(9):829–841. 10.1056/NEJMoa2026982
3. Tannir N, Escudier B, McDermott D, Burotto M, Choueiri TK, Hammers HJ, et al. Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial. J. Clin. Oncol. 42, 2024 (Suppl 4; abstr 363).
4. Burotto M, Powles T, Escudier B, Apolo AB, Bourlon MT, Shah AY, et al. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. J. Clin. Oncol. 41, 2023 (Suppl 6; abstr 603). 10.1200/JCO.2023.41.6_suppl.603
5. Motzer R, Boris Alekseev, Sun-Young R. Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 2021 Apr 8;384(14):1289–1300. 10.1056/NEJMoa2035716
6. Motzer R, Porta C, Masatoshi E, Grunwald V, Hutson TE, Alekseev B, et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a Phase III Study. J. Clin. Oncol. 2024 Apr 10;42(11):1222–1228. 10.1200/JCO.23.01569.
7. Rini BI, Elizabeth RP, Viktor S, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 2019 Mar 21;380(12):1116–1127. 10.1056/NEJMoa1816714
8. Powles T, Plimack ER, Soulieres D, Waddell T, Stus V, Gafanov R, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomized, open-label, phase 3 trial. Lancet Oncol. 2020; 21:1563–1573. 10.1016/S1470-2045(20)30436-8
9. Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med. 2021 Aug 19;385(8):683–694. 10.1056/NEJMoa2106391
10. Goodman RS, Lawless A, Woodford R, Fa’ak F, Tipirneni A, Patrinely RJ, et al. Extended follow-up of chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Netw. Open. 2023;6(8):e2327145–52. 10.1001/jamanetworkopen.2023.27145
11. Patrinely JR, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, et al. Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Oncol. 2021 May 1;7(5):744–748. 10.1001/jamaoncol.2021.0051
12. Barron CC, Isabella S, Yevin C, Elsolh K, Zereshkian A, Gaafour N, et al. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: A systematic review. J. Immunother. Cancer. 2023 Aug 11(8): 1–7. 10.1136/jitc-2022-006500
13. John DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: Long-term implications of toxicity. Nat. Rev. Clin. Oncol. 2022; 19(4): 254–267. 10.1038/s41571-022-00600-w
14. Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat. Med. 2021;27(2):256–263. 10.1038/s41591-020-01211-7
15. Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann. Oncol. 2021; July 32 (7) 917–925. 10.1016/j.annonc.2021.03.204
16. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728. 10.1001/jamaoncol.2018.392
Comments (0)